How This Class Works

The rationale for isolating the C-terminal region of HGH emerged from research in the 1980s and 1990s establishing that full-length growth hormone exerts two pharmacologically distinct sets of effects: anabolic effects mediated primarily via IGF-1 (muscle growth, bone density, glucose regulation), and lipolytic effects concentrated in the C-terminal region. The fat-mobilising activity of the C-terminal fragment operates independently of IGF-1 signalling, making it a target for research into selective lipolysis without the endocrine consequences of full HGH.

The proposed mechanism of lipolytic activity involves stimulation of β3-adrenergic receptors on adipocytes. β3-adrenergic receptor activation promotes the intracellular signalling cascade: adenylyl cyclase activation → elevated cAMP → protein kinase A (PKA) activation → hormone-sensitive lipase (HSL) phosphorylation and activation. HSL is the rate-limiting enzyme in triglyceride breakdown, catalysing the hydrolysis of stored triglycerides into free fatty acids and glycerol for energy substrate use. The class also appears to inhibit lipogenesis — the synthesis and accumulation of new fatty acids in adipocytes — providing a dual mechanism for favouring fat loss over fat gain.

Both compounds in this class are distinguished from GLP-1 agonists and other metabolic peptides by their mechanism: they act directly on adipocyte lipolytic signalling rather than on appetite centres, gut motility, or insulin sensitivity. They are also distinct from the growth hormone secretagogues (GHRPs, GHRH analogues) in that they do not stimulate endogenous GH release or affect the GH/IGF-1 axis.

Research Context

The foundational work mapping the lipolytic activity of HGH to its C-terminal region was conducted in the 1990s. Ng et al. (1990) reported metabolic effects of a synthetic HGH fragment in animal models, and Heffernan and colleagues (2000, 2001) published key data on the effects of the C-terminal fragment and the pharmaceutical derivative AOD-9604 in obese mice, demonstrating fat mass reduction without the growth-promoting and blood glucose effects of full HGH.

AOD-9604 was advanced by Metabolic Pharmaceuticals (Melbourne, Australia) through a clinical development programme, including FDA Investigational New Drug (IND) designation and Phase 2 and Phase 3 trials for obesity. The Phase 3 trials did not meet their primary endpoint for body weight reduction, and the compound was not pursued for pharmaceutical approval. However, the clinical trial programme established human safety data not available for most research peptides. Research interest in this compound class has continued in the peptide research community since the trial programme concluded.

Individual Compound Notes